Fabry disease: The future is in the past

S.J. van der Veen

Fabry disease: The future is in the past

S.J. van der Veen

Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

Abstract

Fabry disease is a rare lysosomal storage disease, caused by pathogenic mutations in the alpha-galactosidase-A gene resulting in a dysfunctional enzyme. Over two decades ago, enzyme replacement therapy (ERT) became available for patients, with approval based on mostly surrogate (pre-clinical) endpoints. Over the years it became evident that treatment may slow down

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Amsterdam
Supervisors/Advisors	Hollak, Carla, Supervisor Langeveld, Mirjam, Co-supervisor van Kuilenburg, André, Co-supervisor
Award date	5 Jul 2023
Print ISBNs	9789464831894
Publication status	Published - 2023

Access to Document

https://hdl.handle.net/11245.1/1feed079-fa97-4ad8-8840-62b604f06b33

Cite this

@phdthesis{ff18e80bb1264f3e8852e794152afbcc,

title = "Fabry disease: The future is in the past",

abstract = "Fabry disease is a rare lysosomal storage disease, caused by pathogenic mutations in the alpha-galactosidase-A gene resulting in a dysfunctional enzyme. Over two decades ago, enzyme replacement therapy (ERT) became available for patients, with approval based on mostly surrogate (pre-clinical) endpoints. Over the years it became evident that treatment may slow down",

author = "\{van der Veen\}, S.J.",

year = "2023",

language = "English",

isbn = "9789464831894",

type = "Phd-Thesis - Research and graduation internal",

school = "University of Amsterdam",

}

TY - THES

T1 - Fabry disease

T2 - The future is in the past

AU - van der Veen, S.J.

PY - 2023

Y1 - 2023

N2 - Fabry disease is a rare lysosomal storage disease, caused by pathogenic mutations in the alpha-galactosidase-A gene resulting in a dysfunctional enzyme. Over two decades ago, enzyme replacement therapy (ERT) became available for patients, with approval based on mostly surrogate (pre-clinical) endpoints. Over the years it became evident that treatment may slow down

AB - Fabry disease is a rare lysosomal storage disease, caused by pathogenic mutations in the alpha-galactosidase-A gene resulting in a dysfunctional enzyme. Over two decades ago, enzyme replacement therapy (ERT) became available for patients, with approval based on mostly surrogate (pre-clinical) endpoints. Over the years it became evident that treatment may slow down

M3 - Phd-Thesis - Research and graduation internal

SN - 9789464831894

ER -

Fabry disease: The future is in the past

Abstract

Access to Document

Fingerprint

Cite this